VANCOUVER, BRITISH COLUMBIA -- (MARKET WIRE) -- September 19, 2006 -- Protiva Biotherapeutics Inc. announced today the intent of the U.S. Defense Threat Reduction Agency to award a US$3.6 million grant to a consortium which includes the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) and Protiva. The project will use Protiva's Stable Nucleic Acid Lipid Particle (SNALP) technology to develop a therapy for hemorrhagic fever viral infection, including the Ebola and Marburg viruses. Protiva's portion of the grant is approximately US$1.4 million.
